Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge (Review)

Abstract

The treatment of patients with metastatic prostate cancer (Pca) is considered to be a long‑standing challenge. conventional treatments for metastatic Pca, such as radical prostatectomy, radiotherapy and androgen receptor‑targeted therapy, induce senescence of Pca cells to a certain extent. While senescent cells can impede tumor growth through the restriction of cell proliferation and increasing immune clearance, the senescent microenvironment may concurrently stimulate the secretion of a senescence‑associated secre‑ tory phenotype and diminish immune cell function, which promotes Pca recurrence and metastasis. resistance to estab‑ lished therapies is the primary obstacle in treating metastatic Pca as it can lead to progression towards an incurable state of disease. Therefore, understanding the molecular mechanisms that underly the progression of Pca is crucial for the devel‑ opment of novel therapeutic approaches. The present study reviews the phenomenon of treatment‑induced senescence in Pca, the dual role of senescence in Pca treatments and the mechanisms through which senescence promotes Pca metas‑ tasis. Furthermore, the present review discusses potential therapeutic strategies to target the aforementioned processes with the aim of providing insights into the evolving therapeutic landscape for the treatment of metastatic PCa.